Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept

NCT00420472 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00420472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00420472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2007
Completion date
Not reported
Enrollment
Not reported
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation